Poorly differentiated oncocytic thyroid carcinoma - diagnostic implications and outcome

Histopathology

Volumn 60, Issue 7, 2012, Pages 1045-1051

  Dettmer, Matthias ^a,b   Schmitt, Anja ^a   Steinert, Hans ^c   Moch, Holger ^c   Komminoth, Paul ^d   Perren, Aurel ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d TRIEMLI HOSPITAL   (Switzerland)

Author keywords

Carcinoma; Oncocytic; Poorly differentiated; Prognosis; Thyroid

Indexed keywords

AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TUMOR SPECIFIC SURVIVAL;

ADENOMA, OXYPHILIC; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SWITZERLAND; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84861478505     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04188.x     Document Type: Article

References (39)

1. Granner DK, Buckwalter JA. Poorly differentiated carcinoma of the thyroid gland. Surg. Gynecol. Obstet. 1963; 116; 650-656.
2. DeLellis RALR, Heitz PU, Eng C, eds. Pathology and genetics of tumours of endocrine organs [World Health Organization classification of tumours 2004]. Lyon: IARC Press, 2004.
3. Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 1983; 52; 1849-1855.
4. Carcangiu ML, Zampi G, Rosai J. Poorly differentiated ('insular') thyroid carcinoma. A reinterpretation of Langhans''wuchernde Struma'. Am. J. Surg. Pathol. 1984; 8; 655-668.
5. Akslen LA, LiVolsi VA. Poorly differentiated thyroid carcinoma - it is important. Am. J. Surg. Pathol. 2000; 24; 310-313.
6. Sobrinho-Simoes M. Poorly differentiated carcinomasa of the thyroid. Endocr. Pathol. 1996; 7; 99-102.
7. Nishiyama RH. Another dissertation on poorly differentiated carcinomas: is it really necessary? Adv. Anat. Pathol. 1999; 6; 281-286.
8. Pilotti S, Collini P, Manzari A, Marubini E, Rilke F. Poorly differentiated forms of papillary thyroid carcinoma: distinctive entities or morphological patterns? Semin. Diagn. Pathol. 1995; 12; 249-255.
9. Volante M, Rapa I, Papotti M. Poorly differentiated thyroid carcinoma: diagnostic features and controversial issues. Endocr. Pathol. 2008; 19; 150-155.
10. Rufini V, Salvatori M, Fadda G et al. Thyroid carcinomas with a variable insular component: prognostic significance of histopathologic patterns. Cancer 2007; 110; 1209-1217.
11. Hiltzik D, Carlson DL, Tuttle RM et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 2006; 106; 1286-1295.
12. Sanders EM Jr, LiVolsi VA, Brierley J, Shin J, Randolph GW. An evidence-based review of poorly differentiated thyroid cancer. World J. Surg. 2007; 31; 934-945.
13. Jung TS, Kim TY, Kim KW et al. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. Endocr. J. 2007; 54; 265-274.
14. Volante M, Collini P, Nikiforov YE et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am. J. Surg. Pathol. 2007; 31; 1256-1264.
15. Martin JD, Elkin DC. Hurthle cell tumors of the thyroid. Ann. Surg. 1939; 110; 169-176.
16. Goldenberg IS. Hurthle cell carcinoma. AMA Arch. Surg. 1953; 67; 495-501.
17. Thomas CG Jr, Buckwalter JA. Poorly differentiated neoplasms of the thyroid gland. Ann. Surg. 1973; 177; 632-642.
18. Ficarra BJ. Hurthle cell adenoma of the thyroid. NY State J. Med. 1952; 52; 1176.
19. Mai KT, Elmontaser G, Perkins DG, Thomas J, Stinson WA. Benign Hurthle cell adenoma with papillary architecture: a benign lesion mimicking oncocytic papillary carcinoma. Int. J. Surg. Pathol. 2005; 13; 37-41.
20. Caplan RH, Abellera RM, Kisken WA. Hurthle cell tumors of the thyroid gland. A clinicopathologic review and long-term follow-up. JAMA 1984; 251; 3114-3117.
21. Schnack-Herbosegg H. [On the so-called Hurthle cell tumor; macrocellular, microalveolar Langhans struma.]. Schweiz Z. Pathol. Bakteriol. 1953; 16; 665-679.
22. Lazzi S, Spina D, Als C et al. Oncocytic (Hurthle cell) tumors of the thyroid: distinct growth patterns compared with clinicopathological features. Thyroid 1999; 9; 97-103.
23. Amt S. Statistisches Amt des Kantons Zürich. Department of Statistics of the Canton Zürich. 2011. Available at: (Accessed 16 March 2011).
24. Dettmer M, Schmitt A, Steinert H et al. Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed? Am. J. Surg. Pathol. 2011; 35; 1866-1872.
25. Asa SL. My approach to oncocytic tumours of the thyroid. J. Clin. Pathol. 2004; 57; 225-232.
26. Volante M, Papotti M. Poorly differentiated thyroid carcinoma: 5years after the 2004 WHO classification of endocrine tumours. Endocr. Pathol. 2010; 21; 1-6.
27. Asioli S, Erickson LA, Righi A et al. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Modern Pathology 2010; 23; 1269-1278.
28. Sobrinho-Simoes M, Maximo V, Castro IV et al. Hurthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance. Int. J. Surg. Pathol. 2005; 13; 29-35.
29. Maximo V, Sobrinho-Simoes M. Hurthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch. 2000; 437; 107-115.
30. Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am. J. Pathol. 2002; 160; 1857-1865.
31. Allia E, Cassoni P, Marrocco T et al. Oxyphilic and non-oxyphilic thyroid carcinoma cell lines differ in expressing apoptosis-related genes. J. Endocrinol. Invest. 2003; 26; 660-667.
32. Eng C, Kiuru M, Fernandez MJ, Aaltonen LA. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat. Rev. Cancer 2003; 3; 193-202.
33. Rosai J. Tumors of the thyroid gland. Washington: Armed Forces Institute of Pathology. 1992.
34. Fitzgerald PJ, Foote FW Jr, Hill RF. Concentration of I131 in thyroid cancer, shown by radioautography; a study of 100 consecutive cases showing the relation of histological structure to the function of thyroid carcinoma. Cancer 1950; 3; 86-105.
35. Yutan E, Clark OH. Hurthle cell carcinoma. Curr. Treat. Options Oncol. 2001; 2; 331-335.
36. Azadian A, Rosen IB, Walfish PG, Asa SL. Management considerations in Hurthle cell carcinoma. Surgery 1995; 118; 711-714; discussion 714-715.
37. Evans HL, Vassilopoulou-Sellin R. Follicular and Hurthle cell carcinomas of the thyroid: a comparative study. Am. J. Surg. Pathol. 1998; 22; 1512-1520.
38. Papotti M, Torchio B, Grassi L, Favero A, Bussolati G. Poorly differentiated oxyphilic (Hurthle cell) carcinomas of the thyroid. Am. J. Surg. Pathol. 1996; 20; 686-694.
39. Volante M, Landolfi S, Chiusa L et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer 2004; 100; 950-957.